Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Poseida Therapeutics Inc (PSTX)

Poseida Therapeutics Inc (PSTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 256,939
  • Shares Outstanding, K 96,958
  • Annual Sales, $ 64,700 K
  • Annual Income, $ -123,430 K
  • 60-Month Beta 0.53
  • Price/Sales 3.96
  • Price/Cash Flow N/A
  • Price/Book 3.02
Trade PSTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.43
  • Number of Estimates 3
  • High Estimate -0.38
  • Low Estimate -0.47
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -34.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.58 +2.64%
on 06/20/24
3.16 -16.14%
on 05/21/24
-0.51 (-16.14%)
since 05/20/24
3-Month
1.87 +41.71%
on 04/16/24
3.55 -25.35%
on 05/16/24
-0.32 (-10.77%)
since 03/20/24
52-Week
1.54 +72.08%
on 06/29/23
4.27 -37.94%
on 03/01/24
+0.26 (+10.88%)
since 06/20/23

Most Recent Stories

More News
Poseida Therapeutics Announces Leadership Transition

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 2.65 (+0.38%)
Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 2.65 (+0.38%)
Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 2.65 (+0.38%)
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering...

PSTX : 2.65 (+0.38%)
Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 2.65 (+0.38%)
Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 2.65 (+0.38%)
Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 2.65 (+0.38%)
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 2.65 (+0.38%)
Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 2.65 (+0.38%)
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...

PSTX : 2.65 (+0.38%)

Business Summary

Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed...

See More

Key Turning Points

3rd Resistance Point 3.23
2nd Resistance Point 3.09
1st Resistance Point 2.87
Last Price 2.65
1st Support Level 2.51
2nd Support Level 2.36
3rd Support Level 2.14

See More

52-Week High 4.27
Fibonacci 61.8% 3.23
Fibonacci 50% 2.90
Last Price 2.65
Fibonacci 38.2% 2.58
52-Week Low 1.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar